Literature DB >> 24366747

In vitro efficacy of corifungin against Acanthamoeba castellanii trophozoites and cysts.

Anjan Debnath1, Josefino B Tunac, Angélica Silva-Olivares, Silvia Galindo-Gómez, Mineko Shibayama, James H McKerrow.   

Abstract

Painful blinding keratitis and fatal granulomatous amebic encephalitis are caused by the free-living amebae Acanthamoeba spp. Several prescription eye medications are used to treat Acanthamoeba keratitis, but the infection can be difficult to control because of recurrence of infection. For the treatment of encephalitis, no single drug was found useful, and in spite of the use of a combination of multiple drugs, the mortality rate remains high. Therefore, efficient, novel drugs are urgently needed for the treatment of amebic keratitis and granulomatous amebic encephalitis. In this study, we identified corifungin, a water-soluble polyene macrolide, as amebicidal. In vitro, it was effective against both the trophozoites and the cysts. Transmission electron microscopy of Acanthamoeba castellanii incubated with corifungin showed the presence of swollen mitochondria, electron-dense granules, degeneration of cytoplasm architecture, and loss of nuclear chromatin structure. These changes were followed by lysis of amebae. Corifungin also induced the encystment process of A. castellanii. There were alterations in the cyst cell wall followed by lysis of the cysts. Corifungin is a promising therapeutic option for keratitis and granulomatous amebic encephalitis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24366747      PMCID: PMC3957901          DOI: 10.1128/AAC.02254-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

Review 1.  Acanthamoeba keratitis update-incidence, molecular epidemiology and new drugs for treatment.

Authors:  D V Seal
Journal:  Eye (Lond)       Date:  2003-11       Impact factor: 3.775

Review 2.  Pathogenic free-living amoebae: epidemiology and clinical review.

Authors:  H Trabelsi; F Dendana; A Sellami; H Sellami; F Cheikhrouhou; S Neji; F Makni; A Ayadi
Journal:  Pathol Biol (Paris)       Date:  2012-04-18

3.  Effect of steroids on Acanthamoeba cysts and trophozoites.

Authors:  K McClellan; K Howard; J Y Niederkorn; H Alizadeh
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-11       Impact factor: 4.799

Review 4.  A novel mechanism for an old drug: amphotericin B in the treatment of visceral leishmaniasis.

Authors:  Amitabha Chattopadhyay; Md Jafurulla
Journal:  Biochem Biophys Res Commun       Date:  2011-11-10       Impact factor: 3.575

5.  Granulomatous amebic encephalitis in a child with acute lymphoblastic leukemia successfully treated with multimodal antimicrobial therapy and hyperbaric oxygen.

Authors:  P Maritschnegg; P Sovinz; H Lackner; M Benesch; A Nebl; W Schwinger; J Walochnik; C Urban
Journal:  J Clin Microbiol       Date:  2010-11-17       Impact factor: 5.948

6.  Cytotoxic activities of alkylphosphocholines against clinical isolates of Acanthamoeba spp.

Authors:  Julia Walochnik; Michael Duchêne; Karin Seifert; Andreas Obwaller; Thomas Hottkowitz; Gerhard Wiedermann; Hansjörg Eibl; Horst Aspöck
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

Review 7.  Opportunistic amoebae: challenges in prophylaxis and treatment.

Authors:  Frederick L Schuster; Govinda S Visvesvara
Journal:  Drug Resist Updat       Date:  2004-02       Impact factor: 18.500

Review 8.  Acanthamoeba spp. as agents of disease in humans.

Authors:  Francine Marciano-Cabral; Guy Cabral
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

9.  Corifungin, a new drug lead against Naegleria, identified from a high-throughput screen.

Authors:  Anjan Debnath; Josefino B Tunac; Silvia Galindo-Gómez; Angélica Silva-Olivares; Mineko Shibayama; James H McKerrow
Journal:  Antimicrob Agents Chemother       Date:  2012-08-06       Impact factor: 5.191

10.  In vitro efficacies of clinically available drugs against growth and viability of an Acanthamoeba castellanii keratitis isolate belonging to the T4 genotype.

Authors:  Abdul Mannan Baig; Junaid Iqbal; Naveed Ahmed Khan
Journal:  Antimicrob Agents Chemother       Date:  2013-05-13       Impact factor: 5.191

View more
  11 in total

1.  Chloroquine has a cytotoxic effect on Acanthamoeba encystation through modulation of autophagy.

Authors:  Bijay Kumar Jha; Hui-Jung Jung; Incheol Seo; Hyun Ah Kim; Seong-Il Suh; Min-Ho Suh; Won-Ki Baek
Journal:  Antimicrob Agents Chemother       Date:  2014-08-11       Impact factor: 5.191

2.  Yersinia pestis Resists Predation by Acanthamoeba castellanii and Exhibits Prolonged Intracellular Survival.

Authors:  Javier A Benavides-Montaño; Viveka Vadyvaloo
Journal:  Appl Environ Microbiol       Date:  2017-06-16       Impact factor: 4.792

3.  Antiprotozoal activity of different Xenorhabdus and Photorhabdus bacterial secondary metabolites and identification of bioactive compounds using the easyPACId approach.

Authors:  Sebnem Hazal Gulsen; Evren Tileklioglu; Edna Bode; Harun Cimen; Hatice Ertabaklar; Derya Ulug; Sema Ertug; Sebastian L Wenski; Mustapha Touray; Canan Hazir; Duygu Kaya Bilecenoglu; Ibrahim Yildiz; Helge B Bode; Selcuk Hazir
Journal:  Sci Rep       Date:  2022-06-24       Impact factor: 4.996

4.  Application of Histone Deacetylase Inhibitors MPK472 and KSK64 as a Potential Treatment Option for Acanthamoeba Keratitis.

Authors:  Hae-Ahm Lee; So-Min Park; Ki-Back Chu; Fu-Shi Quan; Thomas Kurz; Marc Pflieger; Eun-Kyung Moon
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

5.  Development of a Machine Learning-Based Cysticidal Assay and Identification of an Amebicidal and Cysticidal Marine Microbial Metabolite against Acanthamoeba.

Authors:  Brian Shing; Mina Balen; William Fenical; Anjan Debnath
Journal:  Microbiol Spectr       Date:  2022-04-25

6.  Opportunistic free-living amoebal pathogens.

Authors:  Mohammad Ridwane Mungroo; Naveed Ahmed Khan; Sutherland Maciver; Ruqaiyyah Siddiqui
Journal:  Pathog Glob Health       Date:  2021-10-02       Impact factor: 3.735

7.  Management of granulomatous amebic encephalitis: Laboratory diagnosis and treatment.

Authors:  Subhash Chandra Parija; Kp Dinoop; Hrudya Venugopal
Journal:  Trop Parasitol       Date:  2015 Jan-Jun

8.  Acanthamoeba Keratitis and Acanthamoeba Conjunctivitis: A Case Report.

Authors:  Oktay Alver; Mehmet Baykara; Merve YÜrÜk; Nazmiye ÜlkÜ TÜzemen
Journal:  Iran J Parasitol       Date:  2020 Apr-Jun       Impact factor: 1.012

9.  Identification of plicamycin, TG02, panobinostat, lestaurtinib, and GDC-0084 as promising compounds for the treatment of central nervous system infections caused by the free-living amebae Naegleria, Acanthamoeba and Balamuthia.

Authors:  Monica M Kangussu-Marcolino; Gretchen M Ehrenkaufer; Emily Chen; Anjan Debnath; Upinder Singh
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2019-10-22       Impact factor: 4.284

10.  Identification of anisomycin, prodigiosin and obatoclax as compounds with broad-spectrum anti-parasitic activity.

Authors:  Gretchen Ehrenkaufer; Pengyang Li; Erin E Stebbins; Monica M Kangussu-Marcolino; Anjan Debnath; Corin V White; Matthew S Moser; Joseph DeRisi; Jolyn Gisselberg; Ellen Yeh; Steven C Wang; Ana Hervella Company; Ludovica Monti; Conor R Caffrey; Christopher D Huston; Bo Wang; Upinder Singh
Journal:  PLoS Negl Trop Dis       Date:  2020-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.